As many anticancer agents (and other drugs administered for conditions that frequently occur in patients with advanced cancer) are CYP3A4 substrates [11], capivasertib is likely to be administered concomitantly with CYP3A substrates in clinical practice. The gene discussed is CYP3A4; the disease is cancer.